Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Change in Receivables (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Change in Receivables for 3 consecutive years, with $226000.0 as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 62.83% to $226000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$20000.0 through Dec 2025, down 110.81% year-over-year, with the annual reading at -$20000.0 for FY2025, 110.81% down from the prior year.
  • Change in Receivables for Q4 2025 was $226000.0 at Inhibrx Biosciences, up from -$127000.0 in the prior quarter.
  • The five-year high for Change in Receivables was $608000.0 in Q4 2024, with the low at -$768000.0 in Q3 2024.
  • Average Change in Receivables over 3 years is $68444.4, with a median of $64000.0 recorded in 2025.
  • The sharpest move saw Change in Receivables tumbled 19300.0% in 2024, then skyrocketed 83.46% in 2025.
  • Over 3 years, Change in Receivables stood at $447000.0 in 2023, then skyrocketed by 36.02% to $608000.0 in 2024, then plummeted by 62.83% to $226000.0 in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $226000.0, -$127000.0, and $64000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.